Clinical Trials on Blood Coagulation Disorders in Switzerland

Total 4029 results

Triemli Hospital
University of Zurich

Completed

Blood Transfusion and Postoperative Outcome Before and After Implementing a Coagulation Management Algorithm (SONALG)

Coagulation Disorder, Blood

Switzerland
University of Zurich

Recruiting

Blood Loss and Preeclampsia

Blood Loss | Coagulation Disorder | Pre-Eclampsia; Complicating Pregnancy

Switzerland
Centre Hospitalier Universitaire Vaudois

Completed

Bedside Evaluation of Coagulation in Children With Congenital Heart Disease (POCHEMO)

Blood Coagulation Disorder | Congenital Heart Defect

Switzerland
University Hospital, Geneva

Completed

Standardisation of Investigations of Mild Bleeding Disorders (MBD)

Hemorrhagic Disorders

Switzerland
Bayer

Completed

International PMS Study - KOGENATE Bayer

Hemophilia A

Switzerland, France, Spain, Sweden, Austria, Italy, Belgium, Denmark, Greece, Netherlands
University Hospital, Geneva

Completed

DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic (DAPHNE)

Anticoagulants and Bleeding Disorders

Switzerland
University Hospital, Basel, Switzerland

Completed

Acquired Von Willebrand Syndrome in Severe Aortic Stenosis

Bleeding | Aortic Stenosis | Von Willebrand Disease

Switzerland
Novo Nordisk A/S

Completed

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

Spain, Germany, Switzerland, Italy, Israel
University Hospital, Geneva

Recruiting

Bleeding of Unknown Cause: a Swiss Case-control Study (SWISS-BUC)

Bleeding Disorder

Switzerland
Swiss Hemophilia Network

Recruiting

Swiss Hemophilia Registry

Hemophilia and Other Severe Bleeding Disorders

Switzerland
University Hospital, Geneva
Swiss Hemophilia Network

Completed

Pregnancy and Fibrinogen Disorders (FIBRINOGEST)

Hypofibrinogenemia, Congenital | Afibrinogenemia, Congenital | Dysfibrinogenemia, Congenital

Switzerland, France, Slovakia
University of Zurich

Completed

Hemodilution and Coagulopathy With 3 Colloids

Dilutional Coagulopathy

Switzerland
University Children's Hospital, Zurich

Completed

Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.

Hemorrhage | Blood Coagulation Disorders

Switzerland
Genzyme, a Sanofi Company

Completed

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Hemophilia A | Hemophilia B

Bulgaria, United States, United Kingdom, Russian Federation, Switzerland
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
University Hospital, Basel, Switzerland

Completed

Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery

Blood Coagulation Disorders | Coronary Artery Bypass Graft Triple Vessel

Switzerland
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
Sanofi

Completed

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Hemophilia A | Hemophilia B

Bulgaria, Switzerland, United Kingdom, United States, Russian Federation
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Octapharma

Completed

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Congenital Fibrinogen Deficiency | Afibrinogenemia

Iran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
Swedish Orphan Biovitrum
Cerner Enviza

Completed

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Hemophilia A With Inhibitor

France, Ireland, Italy, Norway, Germany, Kuwait, Saudi Arabia, Switzerland
University of Zurich

Completed

Validation of Thrombelastometry (ROTEM®)

Coagulation

Switzerland
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (pathfinder™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Germany, Switzerland, United Kingdom, Italy, Japan, Turkey
Tem Innovations GmbH

Unknown

ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals (ROSI-EVA)

Blood Coagulation Disorders

United States, Austria, Switzerland
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® (pathfinder9)

Haemophilia A

Austria, Spain, Bulgaria, Croatia, Estonia, Hungary, Italy, Lithuania, Portugal, Greece, Germany, Czechia, Slovenia, Switzerland, Slovakia
CSL Behring

Completed

Quality of Life Study of Helixate NexGen

Hemophilia A

Austria, Belgium, France, Germany, Italy, Spain, Switzerland
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Dr Yan Beauverd

Completed

Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure (MPNClot)

Polycythemia Vera | Thrombocythemia, Essential

Switzerland, United Kingdom
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
University Hospital, Geneva

Completed

Quality of Life in Patients With Congenital Afibrinogenemia (QualyAFIB)

Afibrinogenemia, Congenital

France, Turkey, Switzerland, Netherlands, Spain, India, Poland, Canada, United States, Algeria, Egypt, Germany, Italy, Japan, Kuwait, Lebanon, Morocco, Pakistan, Serbia, Slovakia, Tunisia
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (guardian™ 5)

Congenital Bleeding Disorder | Haemophilia A

Italy, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
CSL Behring

Completed

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Congenital Hemophilia A

United States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey
Novo Nordisk A/S

Completed

PROPACT: Retrospective Prophylaxis Patient Case Collection (PROPACT)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Slovakia, Spain, Argentina, Germany, Croatia, Italy, Canada, United Kingdom, Ireland, Sweden, France, United States, Czech Republic, Switzerland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1)

Healthy Volunteers | Haemophilia A With or Without Inhibitors

United States, Germany, Spain, Austria, Bulgaria, Italy, Japan, South Africa, Switzerland, Turkey, United Kingdom, Poland
Bioverativ, a Sanofi company

Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (XTEND-Kids)

Hemophilia A

Turkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Novo Nordisk A/S

Completed

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

Congenital Bleeding Disorder | Glanzmann's Disease

Spain, Bulgaria, Pakistan, Belgium, Germany, France, United Kingdom, Italy, Hungary, Netherlands, United States, Algeria, Austria, Sweden, Switzerland
University Hospital Inselspital, Berne

Completed

Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC) (RheoMECC)

Inflammation | Intracranial Embolism | Extracorporeal Circulation | Blood Coagulation

Switzerland
Biotest
PRA Health Sciences

Completed

Adjusted Fibrinogen Replacement Strategy (AdFIrst)

Bleeding Disorder | Hypofibrinogenemia; Acquired

Belgium, Czechia, Germany, Poland, Spain, Switzerland, United Kingdom
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 PK-guided Dosing (PROPEL)

Hemophilia A

Spain, United States, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Bulgaria, United Kingdom, Switzerland, Ukraine, Turkey, Italy, Norway, France, Austria, Romania, Sweden, Poland, Germany, Hungary, Israel
CSL Behring

Completed

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A | Severe Hemophilia A

United States, Australia, Austria, Canada, Czechia, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Thailand, Ukraine, United...
Novo Nordisk A/S

Recruiting

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

Haemophilia A With or Without Inhibitors

Korea, Republic of, India, China, Canada, Spain, Netherlands, South Africa, United States, Israel, Japan, Poland, United Kingdom, Italy, Lithuania, Portugal, Switzerland, Taiwan
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (STASEY)

Hemophilia A

Canada, Australia, Belgium, India, Germany, Israel, Italy, Spain, Colombia, United Kingdom, Netherlands, Saudi Arabia, Hungary, Guatemala, Russian Federation, Poland, Switzerland, Finland, Panama, Brazil, Mexico, Portugal, Romania, Sw...
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Macedonia, The Former Yugoslav Republic of, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Israel, Russian Federation, Turkey, Lithuania, Poland, Japan, Latvia, Puerto...
Bioverativ, a Sanofi company

Active, not recruiting

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed)

Hemophilia A

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom

Clinical Trials on Blood Coagulation Disorders in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations